Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

On April 29, Novo Nordisk (NVO-2.93%) and Hims & Hers Health (HIMS-4.66%) announced they were collaborating to allow Hims & Hers to sell the weight-loss drug Wegovy. Hims & Hers stock soared on ...

Novo Nordisk has launched its wildly popular weight-loss drug Wegovy in more than 15 countries since 2021 at prices ranging from $200 to almost $2,000 a month, as Eli Lilly also began selling its ...

Novo Nordisk, maker of the popular weight-loss drug Wegovy, says it has started to increase the availability of the drug for people in the United States. CNN values your feedback 1.

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...